

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) April 22, 2004

BECTON, DICKINSON AND COMPANY

(Exact name of registrant as specified in its charter)

| <TABLE> | | |
|---|-----------------------------|---|
| <S> | <C> | <C> |
| New Jersey | 001-4802 | 22-0760120 |
| ----- | ----- | ----- |
| (State or other juris- diction of incorporation) | (Commission File Number) | (IRS Employer Iden- tification Number) |
| 1 Becton Drive, Franklin Lakes, New Jersey | | 07417-1880 |
| ----- | ----- | ----- |
| (Address of principal executive offices) | | (Zip Code) |

Registrant's telephone number, including area code (201) 847-6800

N/A

(Former name or former addresses if changed since last report.)

Item 7. Financial Statements and Exhibits.

(c) Exhibits.

Exhibit 99.1-Press release dated April 22, 2004
announcing financial results for the second fiscal quarter
ended March 31, 2004, which is furnished pursuant
to Item 12.

Item 12. Results of Operations and Financial Condition.

On April 22, 2004, the Company issued a press release announcing
its financial results for the second fiscal quarter ended March
31, 2004. A copy of the press release is furnished as Exhibit 99.1
to this Current Report and is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BECTON, DICKINSON AND COMPANY
(Registrant)

By: /s/ Dean J. Paranicas

Dean J. Paranicas
Vice President,
Corporate Secretary and
Public Policy

Date: April 22, 2004

INDEX TO EXHIBITS

<TABLE>
<CAPTION>

Exhibit
Number

Description of Exhibits

| | |
|------|-------------------------------------|
| <S> | <C> |
| 99.1 | Press release issued April 22, 2004 |

</TABLE>

STATEMENT OF DIFFERENCES

The trademark symbol shall be expressed as.....'TM'

1 Becton Drive
Franklin Lakes, NJ 07417
www.bd.com

News Release

[BD LOGO]
Helping all people
live healthy lives

Contact:

Patricia A. Spinella, Investor Relations - 201-847-5453
Colleen White, Corporate Communications - 201-847-5369

BD ANNOUNCES FISCAL SECOND QUARTER RESULTS

Franklin Lakes, NJ (April 22, 2004) - BD (Becton, Dickinson and Company) (NYSE: BD) today reported record quarterly revenues of \$1.271 billion for the fiscal second quarter ended March 31, 2004, an increase of 12 percent from the same period a year ago. At constant foreign exchange rates, revenues increased 6 percent. Revenue growth in all segments benefited from favorable foreign currency translation, particularly with respect to the Euro.

"We are pleased with the Company's continued strong performance in the second quarter. Solid revenue growth in our BD Medical and BD Biosciences segments reflects contributions from several key areas - prefillable drug delivery devices, diabetes related products and our BD FACSARIA™ cell sorter," said Edward J. Ludwig, Chairman, President and Chief Executive Officer. "Strong revenue growth in nearly all of our international regions was another driving force."

Diluted earnings per share and net income for the quarter were 62 cents and \$165 million, respectively. For the same period in fiscal 2003, diluted earnings per share were 54 cents and net income was \$142 million.

Q2 Segment Results

In the BD Medical segment, worldwide revenues for the quarter were \$683 million, representing an increase of 13 percent over the prior year period. Included in BD Medical revenues were U.S. safety-engineered product sales of \$107 million, as compared with \$98 million in the prior year's quarter, which was offset in part by reduced sales of certain conventional devices in the U.S. due to the transition to safety-engineered devices. Also contributing to the growth of the segment were increased sales of diabetes related products and prefillable drug delivery devices.

In the BD Diagnostics segment, worldwide revenues for the quarter were \$383 million, representing an increase of 7 percent over the prior year period. Revenue growth of 11 percent in the Preanalytical Systems unit of the segment included U.S. safety-engineered device sales of \$75 million, compared with \$68 million in the prior year's quarter, which was offset in part by reduced sales of conventional devices in the U.S. due to the transition to safety-engineered devices. After having experienced a 31 percent increase in the first quarter, due in large part to earlier than usual and exceptionally strong sales of respiratory and flu diagnostic tests in the U.S. and Japan, revenues in the Diagnostic Systems unit of the segment increased 3 percent in the second quarter. For the first half of fiscal 2004, the Diagnostic Systems unit reported 17 percent revenue growth.

In the BD Biosciences segment, worldwide revenues were \$205 million, representing an increase of 17 percent over the prior year period. These results reflected broad market acceptance of the BD FACSARIA™ cell sorter, which BD Biosciences began shipping at the end of the second fiscal quarter of 2003, along with strong sales of flow cytometry reagents in the Immunocytometry Systems and Pharmingen units. Revenue growth was also driven by Discovery Labware products.

Q2 Geographic Results

Second quarter revenues in the U.S. of \$619 million represented an increase of 7 percent over the prior year period. Revenues outside the U.S. of \$651 million represented an increase of 17 percent over the prior year period, or 4 percent at constant foreign exchange rates. International revenues in the second quarter benefited from favorable foreign exchange in substantially all regions. Excluding the impact of favorable foreign exchange, revenues increased in substantially all regions.

Six-month Results

For the six-month period ended March 31, 2004, reported revenues were \$2.470 billion, a 13 percent increase over the same period a year ago, or 6 percent at

constant foreign exchange rates. Diluted earnings per share for the six-month period were \$1.10. For the same period in fiscal 2003, diluted earnings per share were 97 cents. Included in the first half results of fiscal 2004 was a first quarter charge of 11 cents related to certain actions taken in connection with our blood glucose monitoring products. Excluding the charge of 11 cents, pro forma diluted earnings per share for the first half of fiscal 2004 were \$1.21.

Fiscal 2004 Outlook

The Company estimates that its reported diluted earnings per share for fiscal 2004, which includes a charge of 11 cents per share relating to its blood glucose monitoring products, will increase in the range of 10 to 12 percent over the prior period. This estimate is based on fiscal 2003 pro forma earnings per share of \$2.15, which excludes 8 cents of non-cash charges related to the write-down of certain intangible assets and inventory in the BD Biosciences segment.

Conference Call Information

A conference call regarding BD's second quarter results and its expectations for the full fiscal year will be broadcast live on BD's website, www.bd.com/investors, at 10:00 a.m. (ET) Thursday, April 22, 2004. The conference call will be available for replay on BD's website at www.bd.com/investors or at 1-800-283-9732 (domestic) and 1-402-998-1159 (international) through April 29, 2004.

This news release contains certain non-GAAP financial measures. A reconciliation of these and other measures to the comparable GAAP measures is included in the attached financial tables.

BD is a medical technology company that serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. BD manufactures and sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products. For the fiscal year ended September 30, 2003, BD reported total revenues of \$4.528 billion.

This press release, including the section entitled "Fiscal 2004 Outlook," contains certain forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, products and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; uncertainties of litigation; changes in BD's sales volume and product mix; BD's ability to achieve its cost savings objectives; changes in regional, national or foreign economic conditions; increases in energy costs; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; changes in interest or foreign currency exchange rates; delays in product introductions; and changes in healthcare or other governmental regulation, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements.

BECTON DICKINSON AND COMPANY
 CONSOLIDATED INCOME STATEMENTS
 (Unaudited; Amounts in thousands, except per-share data)

<TABLE>
 <CAPTION>

| | Three Months Ended March 31, | | |
|----------------------------|------------------------------|-------------|----------|
| | 2004 | 2003 | % Change |
| <S> | <C> | <C> | <C> |
| REVENUES | \$1,270,523 | \$1,134,041 | 12.0 |
| Cost of products sold | 638,049 | 578,428 | 10.3 |
| Selling and administrative | 338,628 | 298,798 | 13.3 |
| Research and development | 62,554 | 60,034 | 4.2 |

| | | | |
|---------------------------------------|------------|------------|-------|
| TOTAL OPERATING COSTS AND EXPENSES | 1,039,231 | 937,260 | 10.9 |
| ----- | | | |
| OPERATING INCOME | 231,292 | 196,781 | 17.5 |
| Interest expense, net | (7,961) | (8,653) | (8.0) |
| Other expense, net | (3,118) | (1,847) | NM |
| ----- | | | |
| INCOME BEFORE INCOME TAXES | 220,213 | 186,281 | 18.2 |
| Income tax provision | 55,053 | 44,241 | 24.4 |
| ----- | | | |
| NET INCOME | \$ 165,160 | \$ 142,040 | 16.3 |
| ----- | | | |
| EARNINGS PER SHARE | | | |
| Basic | \$ 0.65 | \$ 0.56 | 16.1 |
| Diluted | \$ 0.62 | \$ 0.54 | 14.8 |
| ----- | | | |
| AVERAGE SHARES OUTSTANDING | | | |
| Basic | 253,294 | 254,694 | |
| Diluted | 265,055 | 263,369 | |

</TABLE>

NM - Not Meaningful

Page 1

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)

<TABLE>
<CAPTION>

| | Six Months Ended March 31, | | |
|---------------------------------------|----------------------------|-------------|----------|
| | 2004 | 2003 | % Change |
| ----- | | | |
| <S> | <C> | <C> | <C> |
| REVENUES | \$2,470,054 | \$2,185,689 | 13.0 |
| Cost of products sold | 1,278,933 | 1,128,467 | 13.3 |
| Selling and administrative | 668,248 | 582,979 | 14.6 |
| Research and development | 123,207 | 119,879 | 2.8 |
| ----- | | | |
| TOTAL OPERATING COSTS AND EXPENSES | 2,070,388 | 1,831,325 | 13.1 |
| ----- | | | |
| OPERATING INCOME | 399,666 | 354,364 | 12.8 |
| Interest expense, net | (16,890) | (17,286) | (2.3) |
| Other expense, net | (3,164) | (1,763) | NM |
| ----- | | | |
| INCOME BEFORE INCOME TAXES | 379,612 | 335,315 | 13.2 |
| Income tax provision | 89,050 | 79,637 | 11.8 |
| ----- | | | |
| NET INCOME | \$ 290,562 | \$ 255,678 | 13.6 |
| ----- | | | |
| EARNINGS PER SHARE | | | |
| Basic | \$ 1.15 | \$ 1.00 | 15.0 |
| Diluted | \$ 1.10 | \$ 0.97 | 13.4 |
| ----- | | | |
| AVERAGE SHARES OUTSTANDING | | | |
| Basic | 252,710 | 254,994 | |

Diluted 263,763 263,328

</TABLE>

NM - Not Meaningful

Page 2

BECTON DICKINSON AND COMPANY
 SUPPLEMENTAL REVENUE INFORMATION
 REVENUES BY SEGMENT AND GEOGRAPHIC AREA
 (Unaudited; Amounts in thousands)

<TABLE>
 <CAPTION>

| | Three Months Ended March 31, | | |
|----------------|------------------------------|-------------|----------|
| | 2004 | 2003 | % Change |
| <S> | <C> | <C> | <C> |
| BD MEDICAL | | | |
| United States | \$ 320,687 | \$ 292,794 | 9.5 |
| International | 361,954 | 309,025 | 17.1 |
| TOTAL | \$ 682,641 | \$ 601,819 | 13.4 |
| BD DIAGNOSTICS | | | |
| United States | \$ 211,419 | \$ 206,206 | 2.5 |
| International | 171,456 | 150,594 | 13.9 |
| TOTAL | \$ 382,875 | \$ 356,800 | 7.3 |
| BD BIOSCIENCES | | | |
| United States | \$ 87,317 | \$ 78,545 | 11.2 |
| International | 117,690 | 96,877 | 21.5 |
| TOTAL | \$ 205,007 | \$ 175,422 | 16.9 |
| TOTAL REVENUES | | | |
| United States | \$ 619,423 | \$ 577,545 | 7.3 |
| International | 651,100 | 556,496 | 17.0 |
| TOTAL | \$1,270,523 | \$1,134,041 | 12.0 |

</TABLE>

Page 3

BECTON DICKINSON AND COMPANY
 SUPPLEMENTAL REVENUE INFORMATION
 REVENUES BY SEGMENT AND GEOGRAPHIC AREA
 (Unaudited; Amounts in thousands)

<TABLE>
 <CAPTION>

| | Six Months Ended March 31, | | |
|----------------|----------------------------|-------------|----------|
| | 2004 | 2003 | % Change |
| <S> | <C> | <C> | <C> |
| BD MEDICAL | | | |
| United States | \$ 624,435 | \$ 589,220 | 6.0 |
| International | 685,074 | 584,236 | 17.3 |
| TOTAL | \$1,309,509 | \$1,173,456 | 11.6 |
| BD DIAGNOSTICS | | | |
| United States | \$ 424,336 | \$ 397,738 | 6.7 |
| International | 359,484 | 290,716 | 23.7 |
| TOTAL | \$ 783,820 | \$ 688,454 | 13.9 |

| | | | |
|----------------|------------|------------|------|
| BD BIOSCIENCES | | | |
| United States | \$ 162,346 | \$ 147,882 | 9.8 |
| International | 214,379 | 175,897 | 21.9 |
| TOTAL | \$ 376,725 | \$ 323,779 | 16.4 |

| | | | |
|----------------|-------------|-------------|------|
| TOTAL REVENUES | | | |
| United States | \$1,211,117 | \$1,134,840 | 6.7 |
| International | 1,258,937 | 1,050,849 | 19.8 |
| TOTAL | \$2,470,054 | \$2,185,689 | 13.0 |

</TABLE>

Page 4

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended March 31,
(Unaudited; Amounts in thousands)

<TABLE>
<CAPTION>

| | United States | | |
|--------------------------|---------------|-----------|----------|
| | 2004 | 2003 | % Change |
| <S> | <C> | <C> | <C> |
| BD MEDICAL | | | |
| Medical Surgical Systems | \$196,418 | \$180,731 | 8.7 |
| Diabetes Care | 88,730 | 83,658 | 6.1 |
| Pharmaceutical Systems | 30,276 | 22,795 | 32.8 |
| Ophthalmic Systems | 5,263 | 5,610 | (6.2) |
| TOTAL | \$320,687 | \$292,794 | 9.5 |
| BD DIAGNOSTICS | | | |
| Preanalytical Systems | \$109,464 | \$102,958 | 6.3 |
| Diagnostic Systems | 101,955 | 103,248 | (1.3) |
| TOTAL | \$211,419 | \$206,206 | 2.5 |
| BD BIOSCIENCES | | | |
| Discovery Labware | \$ 24,465 | \$ 23,226 | 5.3 |
| Immunocytometry Systems | 36,129 | 29,141 | 24.0 |
| Clontech | 8,234 | 8,399 | (2.0) |
| Pharming | 18,489 | 17,779 | 4.0 |
| TOTAL | \$ 87,317 | \$ 78,545 | 11.2 |
| TOTAL UNITED STATES | \$619,423 | \$577,545 | 7.3 |

</TABLE>

Page 5

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended March 31, (continued)
(Unaudited; Amounts in thousands)

<TABLE>
<CAPTION>

International

% Change

| | 2004 | 2003 | Reported | FX Neutral | FX Impact |
|--------------------------|-----------|-----------|----------|------------|-----------|
| <S> | <C> | <C> | <C> | <C> | <C> |
| BD MEDICAL | | | | | |
| Medical Surgical Systems | \$187,062 | \$160,667 | 16.4 | 4.6 | 11.8 |
| Diabetes Care | 61,338 | 50,174 | 22.3 | 7.5 | 14.8 |
| Pharmaceutical Systems | 105,100 | 91,011 | 15.5 | 0.1 | 15.4 |
| Ophthalmic Systems | 8,454 | 7,173 | 17.9 | 4.0 | 13.9 |
| TOTAL | \$361,954 | \$309,025 | 17.1 | 3.7 | 13.4 |
| BD DIAGNOSTICS | | | | | |
| Preanalytical Systems | \$ 86,479 | \$ 73,099 | 18.3 | 4.1 | 14.2 |
| Diagnostic Systems | 84,977 | 77,495 | 9.7 | (1.5) | 11.2 |
| TOTAL | \$171,456 | \$150,594 | 13.9 | 1.2 | 12.7 |
| BD BIOSCIENCES | | | | | |
| Discovery Labware | \$ 24,088 | \$ 20,160 | 19.5 | 6.3 | 13.2 |
| Immunocytometry Systems | 67,434 | 54,339 | 24.1 | 10.5 | 13.6 |
| Clontech | 8,553 | 8,889 | (3.8) | (14.3) | 10.5 |
| Pharmingen | 17,615 | 13,489 | 30.6 | 14.7 | 15.9 |
| TOTAL | \$117,690 | \$ 96,877 | 21.5 | 7.9 | 13.6 |
| TOTAL INTERNATIONAL | \$651,100 | \$556,496 | 17.0 | 3.8 | 13.2 |

</TABLE>

Page 6

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended March 31, (continued)
(Unaudited; Amounts in thousands)

<TABLE>
<CAPTION>

| | Total | | | | |
|--------------------------|-------------|-------------|----------|------------|-----------|
| | 2004 | 2003 | % Change | | |
| | 2004 | 2003 | Reported | FX Neutral | FX Impact |
| <S> | <C> | <C> | <C> | <C> | <C> |
| BD MEDICAL | | | | | |
| Medical Surgical Systems | \$ 383,480 | \$ 341,398 | 12.3 | 6.7 | 5.6 |
| Diabetes Care | 150,068 | 133,832 | 12.1 | 6.6 | 5.5 |
| Pharmaceutical Systems | 135,376 | 113,806 | 19.0 | 6.6 | 12.4 |
| Ophthalmic Systems | 13,717 | 12,783 | 7.3 | (0.5) | 7.8 |
| TOTAL | \$ 682,641 | \$ 601,819 | 13.4 | 6.5 | 6.9 |
| BD DIAGNOSTICS | | | | | |
| Preanalytical Systems | \$ 195,943 | \$ 176,057 | 11.3 | 5.4 | 5.9 |
| Diagnostic Systems | 186,932 | 180,743 | 3.4 | (1.4) | 4.8 |
| TOTAL | \$ 382,875 | \$ 356,800 | 7.3 | 2.0 | 5.3 |
| BD BIOSCIENCES | | | | | |
| Discovery Labware | \$ 48,553 | \$ 43,386 | 11.9 | 5.8 | 6.1 |
| Immunocytometry Systems | 103,563 | 83,480 | 24.1 | 15.2 | 8.9 |
| Clontech | 16,787 | 17,288 | (2.9) | (8.3) | 5.4 |
| Pharmingen | 36,104 | 31,268 | 15.5 | 8.6 | 6.9 |
| TOTAL | \$ 205,007 | \$ 175,422 | 16.9 | 9.4 | 7.5 |
| TOTAL REVENUES | \$1,270,523 | \$1,134,041 | 12.0 | 5.5 | 6.5 |

</TABLE>

Page 7

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Six Months Ended March 31,
(Unaudited; Amounts in thousands)

<TABLE>
<CAPTION>

| | United States | | |
|--------------------------|---------------|-------------|----------|
| | 2004 | 2003 | % Change |
| <S> | <C> | <C> | <C> |
| BD MEDICAL | | | |
| Medical Surgical Systems | \$ 394,937 | \$ 373,482 | 5.7 |
| Diabetes Care | 163,579 | 159,154 | 2.8 |
| Pharmaceutical Systems | 54,631 | 44,322 | 23.3 |
| Ophthalmic Systems | 11,288 | 12,262 | (7.9) |
| TOTAL | \$ 624,435 | \$ 589,220 | 6.0 |
| BD DIAGNOSTICS | | | |
| Preanalytical Systems | \$ 216,091 | \$ 203,981 | 5.9 |
| Diagnostic Systems | 208,245 | 193,757 | 7.5 |
| TOTAL | \$ 424,336 | \$ 397,738 | 6.7 |
| BD BIOSCIENCES | | | |
| Discovery Labware | \$ 47,880 | \$ 46,346 | 3.3 |
| Immunocytometry Systems | 64,897 | 52,340 | 24.0 |
| Clontech | 15,087 | 16,262 | (7.2) |
| Pharmingen | 34,482 | 32,934 | 4.7 |
| TOTAL | \$ 162,346 | \$ 147,882 | 9.8 |
| TOTAL UNITED STATES | \$1,211,117 | \$1,134,840 | 6.7 |

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Six Months Ended March 31, (continued)
(Unaudited; Amounts in thousands)

<TABLE>
<CAPTION>

| | International | | | | |
|--------------------------|---------------|------------|------------|-----------|------|
| | 2004 | 2003 | % Change | | |
| Reported | | | FX Neutral | FX Impact | |
| <S> | <C> | <C> | <C> | <C> | <C> |
| BD MEDICAL | | | | | |
| Medical Surgical Systems | \$ 363,386 | \$ 313,435 | 15.9 | 4.0 | 11.9 |
| Diabetes Care | 119,515 | 94,223 | 26.8 | 11.2 | 15.6 |
| Pharmaceutical Systems | 185,944 | 162,729 | 14.3 | (1.4) | 15.7 |
| Ophthalmic Systems | 16,229 | 13,849 | 17.2 | 3.9 | 13.3 |
| TOTAL | \$ 685,074 | \$ 584,236 | 17.3 | 3.6 | 13.7 |
| BD DIAGNOSTICS | | | | | |
| Preanalytical Systems | \$ 164,832 | \$ 139,279 | 18.3 | 4.3 | 14.0 |
| Diagnostic Systems | 194,652 | 151,437 | 28.5 | 15.5 | 13.0 |
| TOTAL | \$ 359,484 | \$ 290,716 | 23.7 | 10.1 | 13.6 |

| | | | | | |
|-------------------------|-------------|-------------|-------|--------|------|
| BD BIOSCIENCES | | | | | |
| Discovery Labware | \$ 45,556 | \$ 38,915 | 17.1 | 3.8 | 13.3 |
| Immunocytometry Systems | 120,810 | 95,192 | 26.9 | 13.3 | 13.6 |
| Clontech | 16,053 | 16,781 | (4.3) | (14.7) | 10.4 |
| Pharmingen | 31,960 | 25,009 | 27.8 | 11.8 | 16.0 |
| | ----- | ----- | | | |
| TOTAL | \$ 214,379 | \$ 175,897 | 21.9 | 8.3 | 13.6 |
| | ----- | ----- | | | |
| TOTAL INTERNATIONAL | \$1,258,937 | \$1,050,849 | 19.8 | 6.2 | 13.6 |
| | ----- | ----- | | | |

</TABLE>

Page 9

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Six Months Ended March 31, (continued)
(Unaudited; Amounts in thousands)

<TABLE>
<CAPTION>

| | Total | | | | |
|--------------------------|-------------|-------------|----------|------------|-----------|
| | 2004 | 2003 | % Change | | |
| | | | Reported | FX Neutral | FX Impact |
| <C> | <C> | <C> | <C> | <C> | |
| <S> | | | | | |
| BD MEDICAL | | | | | |
| Medical Surgical Systems | \$ 758,323 | \$ 686,917 | 10.4 | 4.9 | 5.5 |
| Diabetes Care | 283,094 | 253,377 | 11.7 | 5.9 | 5.8 |
| Pharmaceutical Systems | 240,575 | 207,051 | 16.2 | 3.8 | 12.4 |
| Ophthalmic Systems | 27,517 | 26,111 | 5.4 | (1.6) | 7.0 |
| | ----- | ----- | | | |
| TOTAL | \$1,309,509 | \$1,173,456 | 11.6 | 4.8 | 6.8 |
| | ----- | ----- | | | |
| BD DIAGNOSTICS | | | | | |
| Preanalytical Systems | \$ 380,923 | \$ 343,260 | 11.0 | 5.3 | 5.7 |
| Diagnostic Systems | 402,897 | 345,194 | 16.7 | 11.0 | 5.7 |
| | ----- | ----- | | | |
| TOTAL | \$ 783,820 | \$ 688,454 | 13.9 | 8.1 | 5.8 |
| | ----- | ----- | | | |
| BD BIOSCIENCES | | | | | |
| Discovery Labware | \$ 93,436 | \$ 85,261 | 9.6 | 3.6 | 6.0 |
| Immunocytometry Systems | 185,707 | 147,532 | 25.9 | 17.1 | 8.8 |
| Clontech | 31,140 | 33,043 | (5.8) | (11.0) | 5.2 |
| Pharmingen | 66,442 | 57,943 | 14.7 | 7.8 | 6.9 |
| | ----- | ----- | | | |
| TOTAL | \$ 376,725 | \$ 323,779 | 16.4 | 9.0 | 7.4 |
| | ----- | ----- | | | |
| TOTAL REVENUES | \$2,470,054 | \$2,185,689 | 13.0 | 6.5 | 6.5 |
| | ----- | ----- | | | |

</TABLE>

Page 10

BECTON DICKINSON AND COMPANY
RECONCILIATION TO PRO FORMA AMOUNTS
Six Months Ended March 31,
(Unaudited)

<TABLE>
<CAPTION>

| | 2004 | | |
|-------------|----------|-----------|-----------|
| | As | BGM | Excluding |
| | Reported | Charges * | Charges |
| <S> | <C> | <C> | <C> |
| Diluted EPS | \$1.10 | \$0.11 | \$1.21 |

</TABLE>

* Relates to the fiscal 2004 charge associated with blood glucose monitoring (BGM) products.

BECTON DICKINSON AND COMPANY
RECONCILIATION TO PRO FORMA AMOUNTS
Twelve Months Ended September 30,
(Unaudited)

<TABLE>
<CAPTION>

| | 2003 | | |
|-------------|----------------|-----------------------|----------------------|
| | As Reported | Non-cash Charges** | Excluding Charges |
| <S> | <C> | <C> | <C> |
| Diluted EPS | \$2.07 | \$0.08 | \$2.15 |

** Relates to the fiscal 2003 write-down of certain intangible assets and inventory in the BD Biosciences segment.

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL INFORMATION
Six Months Ended March 31,
(Unaudited; Amounts in thousands)

<TABLE>
<CAPTION>

| | 2004 | | |
|--|----------------------|------------------|----------------------|
| | As Reported | BGM Charges * | Excluding Charges |
| <S> | <C> | <C> | <C> |
| Gross Profit as a % of revenues | \$1,191,121 48.2% | \$45,024 | \$1,236,145 50.0% |
| Operating Income as a % of revenues | 399,666 16.2% | 45,024 | 444,690 18.0% |
| Net Income as a % of revenues | 290,562 11.8% | 27,915 | 318,477 12.9% |

* Relates to the fiscal 2004 charge associated with blood glucose monitoring (BGM) products.